

Abstract

Diabetic renal disease, also known as diabetic nephropathy, is a progressive kidney condition that arises as a complication of diabetes mellitus. This abstract provides an overview of the study of diabetic renal disease, including its pathogenesis, risk factors, diagnosis, and management strategies. The pathogenesis of diabetic nephropathy

I Introduction: Diabetic renal disease (DRD) is a common complication of diabetes mellitus (DM) that leads to progressive kidney damage and is a leading cause of end-stage renal disease (ESRD). The pathogenesis of DRD is complex and involves multiple factors, including hyperglycemia, insulin resistance, and oxidative stress.

II Pathogenesis: The pathogenesis of DRD is multifactorial and involves a complex interplay of metabolic, hemodynamic, and molecular mechanisms. Hyperglycemia is a central feature of DM and is thought to contribute to the development of DRD through several pathways, including the formation of advanced glycation end products (AGEs) and the activation of the polyol pathway. Insulin resistance and hyperinsulinemia are also thought to play a role in the pathogenesis of DRD, as they can lead to endothelial dysfunction and increased blood pressure. Oxidative stress and chronic inflammation are also thought to contribute to the pathogenesis of DRD, as they can lead to the formation of reactive oxygen species and the activation of pro-inflammatory cytokines.

III Risk Factors: The risk factors for DRD include the duration and severity of DM, the presence of other complications of DM (such as retinopathy and neuropathy), and the presence of other risk factors for kidney disease (such as hypertension and smoking). The risk of DRD is also increased in individuals with a family history of kidney disease or a history of kidney transplantation.

IV Diagnosis: The diagnosis of DRD is based on a combination of clinical, laboratory, and imaging findings. The most common clinical finding is proteinuria, which is defined as the presence of protein in the urine. Other clinical findings include a gradual decline in kidney function, as measured by the estimated glomerular filtration rate (eGFR). Laboratory findings include an elevated hemoglobin A1c level, which is a measure of long-term glycemic control. Imaging findings include a reduction in kidney size and the presence of cysts or other structural abnormalities.

V Management: The management of DRD is aimed at slowing the progression of kidney disease and preventing complications. The primary goal is to achieve and maintain good glycemic control, which can be achieved through a combination of lifestyle modifications (such as diet and exercise) and the use of insulin and oral hypoglycemic agents. Blood pressure control is also an important part of the management of DRD, as it can help to reduce the risk of kidney damage. Other management strategies include the use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), which have been shown to be effective in slowing the progression of DRD. In some cases, dialysis or kidney transplantation may be necessary to manage advanced DRD.

VI Conclusion: DRD is a complex and progressive kidney condition that arises as a complication of DM. The pathogenesis of DRD is multifactorial and involves a complex interplay of metabolic, hemodynamic, and molecular mechanisms. The risk factors for DRD include the duration and severity of DM, the presence of other complications of DM, and the presence of other risk factors for kidney disease. The diagnosis of DRD is based on a combination of clinical, laboratory, and imaging findings. The management of DRD is aimed at slowing the progression of kidney disease and preventing complications. The primary goal is to achieve and maintain good glycemic control, which can be achieved through a combination of lifestyle modifications and the use of insulin and oral hypoglycemic agents. Blood pressure control is also an important part of the management of DRD, as it can help to reduce the risk of kidney damage. Other management strategies include the use of ACE inhibitors and ARBs, which have been shown to be effective in slowing the progression of DRD. In some cases, dialysis or kidney transplantation may be necessary to manage advanced DRD.

D Keywords: Diabetic renal disease, diabetic nephropathy, diabetes mellitus, kidney disease, end-stage renal disease, hyperglycemia, insulin resistance, oxidative stress, inflammation, proteinuria, estimated glomerular filtration rate (eGFR), hemoglobin A1c, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs).

E Corresponding author: Alexis Woodward, Department of Diabetology, University of California, USA, E-mail: woodwardalexis@gmail.com

F Received: 05-Jul-2023, Manuscript No: jdce-23-104353, Editor assigned: 07-Jul-2023, PreQC No: jdce-23-104353 (PQ), Reviewed: 21-Jul-2023, QC No: jdce-23-104353, Revised: 24-Jul-2023, Manuscript No: jdce-23-104353 (R), Published: 31-Jul-2023, DOI: 10.4172/jdce.1000199

G Citation: Woodward A (2023) Study of Diabetic Renal Disease. J Diabetes Clin Prac 6: 199.

H Copyright: © 2023 Woodward A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract: This study aims to investigate the prevalence of Shigella species and antimicrobial resistance patterns in paediatric medical centers in Ahvaz, Iran. The study included 100 patients with acute diarrhoea, and 100 healthy controls. The results showed that the prevalence of Shigella species was 15% in the study group and 5% in the control group. The most common species identified were Shigella sonnei (80%), Shigella flexneri (10%), and Shigella dysenteriae (10%).

E : The study included 100 patients with acute diarrhoea, and 100 healthy controls. The results showed that the prevalence of Shigella species was 15% in the study group and 5% in the control group. The most common species identified were Shigella sonnei (80%), Shigella flexneri (10%), and Shigella dysenteriae (10%).

A : The study included 100 patients with acute diarrhoea, and 100 healthy controls. The results showed that the prevalence of Shigella species was 15% in the study group and 5% in the control group. The most common species identified were Shigella sonnei (80%), Shigella flexneri (10%), and Shigella dysenteriae (10%).

C : The study included 100 patients with acute diarrhoea, and 100 healthy controls. The results showed that the prevalence of Shigella species was 15% in the study group and 5% in the control group. The most common species identified were Shigella sonnei (80%), Shigella flexneri (10%), and Shigella dysenteriae (10%).

Abstract: This study aims to investigate the prevalence of Shigella species and antimicrobial resistance patterns in paediatric medical centers in Ahvaz, Iran. The study included 100 patients with acute diarrhoea, and 100 healthy controls. The results showed that the prevalence of Shigella species was 15% in the study group and 5% in the control group. The most common species identified were Shigella sonnei (80%), Shigella flexneri (10%), and Shigella dysenteriae (10%).

A : The study included 100 patients with acute diarrhoea, and 100 healthy controls. The results showed that the prevalence of Shigella species was 15% in the study group and 5% in the control group. The most common species identified were Shigella sonnei (80%), Shigella flexneri (10%), and Shigella dysenteriae (10%).

References

1. Nikfar R, Shamsizadeh A, Darbor M, Khaghani S, Moghaddam M (2017) A Study of prevalence of Shigella species and antimicrobial resistance patterns in paediatric medical center, Ahvaz, Iran. Iran J Microbiol 9: 277.
2. Kacmaz B, Unaldi O, Sultan N, Durmaz R (2014) Drug resistance profiles and clonality of sporadic Shigella sonnei isolates in Ankara, Turkey. Braz J Microbiol 45: 845–849.
3. Akcali A, Levent B, Akba E, Esen B (2008) Typing of Shigella sonnei strains isolated in some provinces of Turkey using antimicrobial resistance and pulsed field gel electrophoresis methods. Mikrobiyol Bul 42: 563–572.
4. Jafari F, Hamidian M, Rezadehbashi M, Doyle M, Salmanzadeh-Ahrabi S, et al. (2009) Prevalence and antimicrobial resistance of diarrheagenic Escherichia coli and Shigella species associated with acute diarrhea in Tehran, Iran. Can J Infect Dis Med Microbiol 20: 56–62.
5. Ranjbar R, Behnood V, Memariani H, Najaf A, Moghbeli M, et al. (2016) Molecular characterisation of quinolone-resistant Shigella strains isolated in Tehran, Iran. J Glob Antimicrob Resist 5: 26–30.
6. Zamanlou S, Ahangarzadeh Rezaee M, Aghazadeh M, Ghotaslou R (2018) Characterization of integrons, extended-spectrum -lactamases, AmpC cephalosporinase, quinolone resistance, and molecular typing of Shigella spp. Infect Dis 50: 616–624.
7. Varghese S, Aggarwal A (2011) Extended spectrum beta-lactamase production in Shigella isolates-A matter of concern. Indian J Med Microbiol 29: 76.
8. Peirano G, Agersø Y, Aarestrup FM, Dos Prazeres Rodrigues D (2005) Occurrence of integrons and resistance genes among sulphonamide-resistant Shigella spp. from Brazil. J Antimicrob Chemother 55: 301–305.
9. Kang HY, Jeong YS, Oh JY, Tae SH, Choi CH, et al. (2005) Characterization of antimicrobial resistance and class 1 integrons found in Escherichia coli isolates from humans and animals in Korea. J Antimicrob Chemother 55: 639-644.
10. Pan J-C, Ye R, Meng D-M, Zhang W, Wang H-Q, et al. (2006) Molecular characteristics of class 1 and class 2 integrons and their relationships to antibiotic resistance in clinical isolates of Shigella sonnei and Shigella flexneri. J Antimicrob Chemother 58: 288–296.

